China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
Home-grown innovative drugs make up most of the medicines China’s drug regulator has approved for sale so far this year, underscoring the country’s biotech boom. Of the 19 innovative drugs cleared by the National Medical Products Administration (NMPA), 15 came from domestic companies, according to the regulator’s website as of May 21. These include sonrotoclax, developed by global biopharmaceutical firm BeOne, for treating certain adult blood cancers. The regulator overhauled
China's National Medical Products Administration (NMPA) has approved 19 innovative drugs for sale this year, with 15 originating from domestic companies. This marks a significant increase in home-grown pharmaceutical development and highlights the country's burgeoning biotech sector. Among the approved treatments is sonrotoclax, a new therapy for specific adult blood cancers developed by the biopharmaceutical firm BeOne.
This trend indicates China's growing self-sufficiency and competitiveness in the global pharmaceutical innovation landscape.
📌 Kaynak
Bu özet SCMP Tech kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →